Lifecore Biomedical Inc (LFCR) ニュース

Form 8-K - Current report

Lifecore Biomedical Completes Incremental Liquidity Initiatives

CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the...

Form 8-K - Current report

Form 8-K - Current report

Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report

CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”...

Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress

Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Provides Fiscal...

Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update

CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or...

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall...

Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023

CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 8-K - Current report

Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal

CHASKA, Minn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”...

Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities